| JOURNAL HOME | CME HOME | THIS MONTH | PAST ISSUES | ETOC | COLLECTIONS |
| AUTHORS | REVIEWERS | EDITORIAL BOARD | FEEDBACK | RSS | HELP |
| ||||||||||||||
| ||||||||||||||
|
|
|
|
||||||||||||
|
||||||||||||||
Departments of *Anesthesiology and Biomathematical Sciences, Mount Sinai Medical Center, New York, New York
Address correspondence and reprint requests to Galina Leyvi, Department of Anesthesiology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467-2490. Address e-mail to galina743{at}pol.net
Activated clotting time (ACT) is a test used in the operating room for monitoring heparin effect. However, ACT does not correlate with heparin levels because of its lack of specificity for heparin and its variability during hypothermia and hemodilution on cardiopulmonary bypass (CPB). A modified ACT using maximal activation of Factor XII, MAX-ACT (Actalyke MAX-ACT; Array Medical, Somerville, NJ), may be less variable and more closely related to heparin levels. We compared MAX-ACT with ACT in 27 patients undergoing CPB. We measured ACT, MAX-ACT, temperature, and hematocrit at six time points: baseline; postheparin; on CPB 30, 60, and 90 min; and postprotamine. Additionally, we assessed anti-Factor Xa heparin activity and antithrombin III activity at four of these six time points. With institution of CPB and hemodilution, MAX-ACT and ACT did not change significantly but had a tendency to increase, whereas concomitant heparin levels decreased (P = 0.065). Neither test correlated with heparin levels. ACT and MAX-ACT did not differ during normothermia but did during hypothermia, and ACT was significantly longer than MAX-ACT (P = 0.009). At the postheparin time point, ACT-heparin sensitivity (defined as [ACT postheparin - ACT baseline]/[heparin concentration postheparin - heparin concentration baseline]) was greater than MAX-ACT-heparin sensitivity (analogous calculation for MAX-ACT; 520 [266 - 9366] s · U-1 · mL-1 vs 468 [203 - 8833] s · U-1 · mL-1; P = 0.022).
Implications: MAX-ACT (a new activated clotting time [ACT] test) uses more maximal clotting activation in vitro and, although it is less susceptible to increase because of hypothermia and hemodilution than ACT, lack of correlation with heparin levels remains a persistent limitation.
This article has been cited by other articles:
|
|
 |
|
  M. T. Ganter, S. Dalbert, K. Graves, R. Klaghofer, A. Zollinger, and C. K. Hofer Monitoring Activated Clotting Time for Combined Heparin and Aprotinin Application: An In Vitro Evaluation of a New Aprotinin-Insensitive Test Using SONOCLOT Anesth. Analg., August 1, 2005; 101(2): 308 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A Spinler, A. K Wittkowsky, E. A Nutescu, and M. A Smythe Anticoagulation Monitoring Part 2: Unfractionated Heparin and Low-Molecular-Weight Heparin Ann. Pharmacother., July 1, 2005; 39(7): 1275 - 1285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Chavez, D. E. Foley, C. C. Snider, J. C. Howell, E. Cohen, R. A. Muenchen, and R. C. Carroll A Novel Thrombelastograph(R) Tissue Factor/Kaolin Assay of Activated Clotting Times for Monitoring Heparin Anticoagulation During Cardiopulmonary Bypass Anesth. Analg., November 1, 2004; 99(5): 1290 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Smythe and A. Caffee Anticoagulation Monitoring Journal of Pharmacy Practice, October 1, 2004; 17(5): 317 - 326. [Abstract] [PDF]
|
|
|
|
 |
|
 P. J. Santrach Devices for Monitoring Heparin and Protamine in the Operating Room Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2003; 7(4): 379 - 385. [Abstract] [PDF]
|
|
|
|
|
|
A. Koster, G. Despotis, M. Gruendel, T. Fischer, M. Praus, H. Kuppe, and J. H. Levy The Plasma Supplemented Modified Activated Clotting Time for Monitoring of Heparinization During Cardiopulmonary Bypass: A Pilot Investigation Anesth. Analg., July 1, 2002; 95(1): 26 - 30. [Abstract] [Full Text] [PDF]
|
|
|
